NSCLC growth and metastasis depend on the generation of new blood vessels by angiogenesis (8), making this process an anti-cancer target exploited by drugs, such as bevacizumab (9, 10), a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) (11). Here, VEGFA is linked to cancer.